Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Cross Below 200-Day Moving Average – What’s Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.32 and traded as low as $5.84. Enanta Pharmaceuticals shares last traded at $5.88, with a volume of 166,938 shares changing hands.

Analyst Ratings Changes

Several research firms have recently weighed in on ENTA. JMP Securities reiterated a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Price Performance

The stock has a market capitalization of $125.01 million, a P/E ratio of -1.18 and a beta of 0.48. The stock has a 50 day simple moving average of $6.38 and a two-hundred day simple moving average of $8.30.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Sell-side analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jay R. Luly purchased 45,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The shares were bought at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the transaction, the chief executive officer now owns 846,638 shares of the company’s stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 13.89% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth about $26,000. Tower Research Capital LLC TRC boosted its position in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after buying an additional 2,274 shares during the period. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $58,000. Squarepoint Ops LLC acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at approximately $66,000. Finally, Velan Capital Investment Management LP acquired a new position in Enanta Pharmaceuticals in the 4th quarter valued at approximately $75,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.